Overall Score

Growth

Revenue base remains very small at $0.28/share, limiting scale.

TTM margins are deeply negative, with gross margin at -3.2% and operating margin at -33.3%.

R&D spend is high at 19.9% of revenue, but it has not yet translated into profitable growth.

Profitability

TTM return on equity is -160.3% and return on invested capital is -171.9%, indicating severe value destruction.

Operating cash flow and free cash flow are both negative on a TTM basis.

Interest coverage is deeply negative, reflecting ongoing operating losses.

Financial Health

Current ratio is 2.27 and quick ratio is 1.99, suggesting adequate short-term liquidity.

Debt levels are modest, with debt-to-equity at 0.54 and net debt to EBITDA near 0.13.

Cash per share of $3.10 exceeds book value per share of $3.55 only modestly, leaving limited balance-sheet cushion.

Valuation

EV/Sales of 7.85 is rich for a company with negative margins and negative cash flow.

Price-to-sales of 12.0 implies the market is still pricing in substantial future growth.

Positive book value and net current asset value provide some asset support, but not enough to offset operating losses.